OTCPK:FRTX - Post Discussion
Post by
TheeRook on Feb 11, 2021 4:46am
COVID-19 Vaccine Opportunity
Summary
Brickell has rights to commercialize Japanse partner's AnGes proprietary COVID-19 plasmid DNA vaccine in the U.S., South America and certain emerging markets per a September 2020 announcement.
In September 2020 Japan's government awarded The University of Osaka and its COVID-19 vaccine development partner Anges $106M because this group is signifcantly ahead of any vaccine developers in Japan.
AnGes COVID-19 vaccine is undergoing Phase 3 in Japan having successfully cleared all prior hurdles. An important feature of thisvaccine is that it can be quickly reformulated to overcome mutations.
Two analysts recently assigned a Buy recommendation with a consensus $5.5/share price target on BBI stock. The company currently has over $30M in cash which is sufficient to support operations beyond the top line results of the U.S. pivotal Phase 3 program on its main program is going after a multi-billion dollar underserved market named Hyperhydrosis.
Following an agreement with Bharat Biotech to commercialize its COVID-19 vaccine candidate COVAXIN in the U.S., Ocugen shares jumped 970% ($16 or $2.5B MC). Brickell could follow Ocugen's steps shortly.
https://seekingalpha.com/instablog/50857529-johnsoriaknows/5551164-brickell-bbi-reluctant-1_1-share-covidminus-19-vaccine-play-be-next-ocugen-capitalizing-on
Be the first to comment on this post